Cargando…

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

A newer generation of anti-cancer drugs targeting underlying somatic genetic driver events have resulted in high single-agent or single-pathway response rates in selected patients, but few patients achieve complete responses and a sizeable fraction of patients relapse within a year. Thus, there is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedman, Adam A., Amzallag, Arnaud, Pruteanu-Malinici, Iulian, Baniya, Subash, Cooper, Zachary A., Piris, Adriano, Hargreaves, Leeza, Igras, Vivien, Frederick, Dennie T., Lawrence, Donald P., Haber, Daniel A., Flaherty, Keith T., Wargo, Jennifer A., Ramaswamy, Sridhar, Benes, Cyril H., Fisher, David E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604168/ https://www.ncbi.nlm.nih.gov/pubmed/26461489 http://dx.doi.org/10.1371/journal.pone.0140310

Ejemplares similares

Detection of Dysregulated Protein Association Networks by High-Throughput Proteomics Predicts Cancer Vulnerabilities
por: Lapek, John D., et al.
Publicado: (2017)

Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets
por: Amzallag, Arnaud, et al.
Publicado: (2019)

Automatic Annotation of Spatial Expression Patterns via Sparse Bayesian Factor Models
por: Pruteanu-Malinici, Iulian, et al.
Publicado: (2011)

Automated annotation of gene expression image sequences via non-parametric factor analysis and conditional random fields
por: Pruteanu-Malinici, Iulian, et al.
Publicado: (2013)

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
por: Sabbatino, Francesco, et al.
Publicado: (2014)

Small molecules facilitate rapid and synchronous iPSC generation
por: Bar-Nur, Ori, et al.
Publicado: (2014)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
por: Cooper, Zachary A, et al.
Publicado: (2013)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
por: Chu, Jie Sheng, et al.
Publicado: (2013)

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
por: Estevez-Garcia, Purificacion, et al.
Publicado: (2012)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma
por: Setyo, Laura C., et al.
Publicado: (2023)

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
por: Michael, M, et al.
Publicado: (2010)

Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
por: Berardi, Rossana, et al.
Publicado: (2015)

Small Molecular-Sized Artesunate Attenuates Ocular Neovascularization via VEGFR2, PKCα, and PDGFR Targets
por: Zong, Yao, et al.
Publicado: (2016)

S1PR1 and VEGFR2 – a synergy that promotes tumor angiogenesis?
por: Balaji Ragunathrao, Vijay Avin, et al.
Publicado: (2020)

VEGFR2(+)PDGFRβ(+) circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI)
por: Jones, Rosemary, et al.
Publicado: (2009)

PDGFRβ regulates craniofacial development through homodimers and functional heterodimers with PDGFRα
por: Fantauzzo, Katherine A., et al.
Publicado: (2016)

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
por: Kim, Hyungsoo, et al.
Publicado: (2015)

Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients
por: Avril, Stefanie, et al.
Publicado: (2017)

Rapid clearance of epigenetic protein reporters from wound edge cells in Drosophila larvae does not depend on the JNK or PDGFR/VEGFR signaling pathways
por: Anderson, Aimee E., et al.
Publicado: (2014)

Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells
por: Wu, Erxi, et al.
Publicado: (2008)

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
por: Zhou, Yuanfeng, et al.
Publicado: (2012)

Structural optimization and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential VEGFR-2/PDGFRβ inhibitors
por: Yang, Ting-Hsuan, et al.
Publicado: (2017)

Deregulation of VEGFR-2 and PDGFR Expression and Microvascular Density in a Triple-Negative Model of Canine Malignant Mammary Tumors with Lymph Node or Lung Metastasis
por: dos Anjos, Denner Santos, et al.
Publicado: (2019)

A microfluidic device and computational platform for high throughput live imaging of gene expression
por: Busch, Wolfgang, et al.
Publicado: (2012)

Genomics of PDGFR-rearranged hypereosinophilic syndrome
por: Rheinbay, Esther, et al.
Publicado: (2023)

VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-β play important roles in promoting immature and inflammatory intraplaque angiogenesis
por: Mao, Yang, et al.
Publicado: (2018)

PDGFR‐β and kidney fibrosis
por: Ortiz, Alberto
Publicado: (2020)

Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells
por: Pruteanu, Lavinia-Lorena, et al.
Publicado: (2020)

Transactivation of PDGFRβ by dopamine D4 receptor does not require PDGFRβ dimerization
por: Chi, Sum Shing, et al.
Publicado: (2010)

PDGFR in PDGF-BB/PDGFR Signaling Pathway Does Orchestrates Osteogenesis in a Temporal Manner
por: Wang, Fangqian, et al.
Publicado: (2023)

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Gene expression-based screening for inhibitors of PDGFR signaling
por: Antipova, Alena A, et al.
Publicado: (2008)

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
por: Song, Yan, et al.
Publicado: (2021)

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ()
por: Vella, Laura J., et al.
Publicado: (2017)

Is PDGFR an important target for E-3810?
por: Damia, Giovanna, et al.
Publicado: (2012)

The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer
por: Jansson, Sara, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2gbqnn70i0jn305mt1ui26657c